Literature DB >> 19486338

Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma.

Kazuhito Morioka1, Chizu Tanikawa, Kensuke Ochi, Yataro Daigo, Toyomasa Katagiri, Hirotaka Kawano, Hiroshi Kawaguchi, Akira Myoui, Hideki Yoshikawa, Norifumi Naka, Nobuto Araki, Ikuo Kudawara, Makoto Ieguchi, Kozo Nakamura, Yusuke Nakamura, Koichi Matsuda.   

Abstract

Osteosarcoma is the most prevalent bone malignant tumor in children and adolescents, and displays heterogeneous histology and high propensity for distant metastasis. Although adjuvant chemotherapy remarkably improved treatment outcome over the past few decades, prognosis for osteosarcoma patients with pulmonary metastasis is still unsatisfactory. To identify novel therapeutic targets for osteosarcoma, we investigated the gene expression profile of osteosarcomas by cDNA microarray analysis and found transactivation of receptor tyrosine kinase-like orphan receptor 2 (ROR2) expression in the majority of osteosarcoma samples. Treatment of osteosarcoma cell lines with siRNA against ROR2 significantly inhibited cell proliferation and migration. We also identified wingless-type MMTV integration site family, member 5B (WNT5B) as a putative ROR2 ligand and that the physiological interaction of WNT5B and ROR2 could enhance cell migration, indicating the possible roles of ROR2 and WNT5B in the metastatic property of osteosarcoma cells. Taken together, our findings revealed that the WNT5B/ROR2 signaling pathway is a promising therapeutic target for osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19486338     DOI: 10.1111/j.1349-7006.2009.01165.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  39 in total

Review 1.  The role of Ryk and Ror receptor tyrosine kinases in Wnt signal transduction.

Authors:  Jennifer Green; Roel Nusse; Renée van Amerongen
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-02-01       Impact factor: 10.005

2.  Essential role of SH3GL1 in interleukin-6(IL-6)- and vascular endothelial growth factor (VEGF)-triggered p130cas-mediated proliferation and migration of osteosarcoma cells.

Authors:  En-Qi Li; Jin-Li Zhang
Journal:  Hum Cell       Date:  2017-07-12       Impact factor: 4.174

Review 3.  Molecular genetic studies of gene identification for osteoporosis: the 2009 update.

Authors:  Xiang-Hong Xu; Shan-Shan Dong; Yan Guo; Tie-Lin Yang; Shu-Feng Lei; Christopher J Papasian; Ming Zhao; Hong-Wen Deng
Journal:  Endocr Rev       Date:  2010-03-31       Impact factor: 19.871

4.  Clinically Relevant Molecular Subtypes in Leiomyosarcoma.

Authors:  Xiangqian Guo; Vickie Y Jo; Anne M Mills; Shirley X Zhu; Cheng-Han Lee; Inigo Espinosa; Marisa R Nucci; Sushama Varma; Erna Forgó; Trevor Hastie; Sharon Anderson; Kristen Ganjoo; Andrew H Beck; Robert B West; Christopher D Fletcher; Matt van de Rijn
Journal:  Clin Cancer Res       Date:  2015-04-20       Impact factor: 12.531

5.  Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia.

Authors:  Abdul Salam Khan; Mohammad Hojjat-Farsangi; Amir Hossein Daneshmanesh; Lotta Hansson; Parviz Kokhaei; Anders Österborg; Håkan Mellstedt; Ali Moshfegh
Journal:  Tumour Biol       Date:  2016-04-16

6.  Knockdown of receptor tyrosine kinase-like orphan receptor 2 inhibits cell proliferation and colony formation in osteosarcoma cells by inducing arrest in cell cycle progression.

Authors:  Jianjun Huang; Ying Shi; Hui Li; Dunyong Tan; Meisongzhu Yang; Xiang Wu
Journal:  Oncol Lett       Date:  2015-10-12       Impact factor: 2.967

7.  Proteomic signatures associated with p53 mutational status in lung adenocarcinoma.

Authors:  Ayumu Taguchi; Oliver Delgado; Müge Celiktaş; Hiroyuki Katayama; Hong Wang; Adi F Gazdar; Samir M Hanash
Journal:  Proteomics       Date:  2014-11-20       Impact factor: 3.984

Review 8.  Wnt signaling and the control of human stem cell fate.

Authors:  J K Van Camp; S Beckers; D Zegers; W Van Hul
Journal:  Stem Cell Rev Rep       Date:  2014-04       Impact factor: 5.739

9.  Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.

Authors:  Lyndsay V Rhodes; Chandra R Tate; H Chris Segar; Hope E Burks; Theresa B Phamduy; Van Hoang; Steven Elliott; Diari Gilliam; F Nell Pounder; Muralidharan Anbalagan; Douglas B Chrisey; Brian G Rowan; Matthew E Burow; Bridgette M Collins-Burow
Journal:  Breast Cancer Res Treat       Date:  2014-05-09       Impact factor: 4.872

Review 10.  Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt.

Authors:  Michael P O'Connell; Ashani T Weeraratna
Journal:  Pigment Cell Melanoma Res       Date:  2009-08-25       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.